Providence Health names new COO

Cheryl Morrison-Bornstein has been named chief operating officer of Providence Health Plan, a Portland, Oregon-based not-for-profit health plan. 

In her new role, Morrison-Bornstein will oversee the day-to-day operational and administrative functions of the health plan and design innovative operating models to support the organization's overall growth strategy, effective June 6.

Morrison-Bornstein joins Providence from Blue Shield of California, where she served as vice president of growth operations, commercial and consumer markets. She has nearly 20 years of healthcare experience, and has played a key role in developing and executing successful growth strategies across multiple organizations. Prior to Blue Shield of California, she served as vice president of client growth strategy at UnitedHealth Group – OptumRx.

"We are thrilled to welcome Cheryl to PHP. Her vast experience and dedication to being an impactful, results-driven leader will have an immediate impact on the organization," Don Antonucci, CEO of Providence Health Plan (PHP), said in a statement. "Throughout her impressive career, Cheryl has inspired her team members by delivering a clear vision resulting in the successful growth of the organizations where she previously served. Cheryl will play a crucial role in the ongoing transformation of PHP, especially as we look for new and innovative ways to better serve members while we continue to put their needs first.”

The new hire comes as healthcare executives have been increasingly moving around, with hospital CEOs joining the Great Resignation and departing from their roles at a record clip. 

Providence recently reported big losses for the first quarter of 2022. The health plan reported $359 million in investment losses, which the healthcare organization blamed on market volatility. 

“Though external economic pressures continue to bear down on health systems across the country, Providence remains steadfast in our commitment to meeting the needs of our communities,” Providence President and CEO Rod Hochman, MD, said in a statement. “Just as our founders did more than 160 years ago, we will continue to respond to the times to ensure we can bring our healing Mission to those in need well into the future.” 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.